Theralink Technologies, Inc. THER

THER Company Overview

Theralink Technologies, Inc. (“Theralink”) is a precision medicine and diagnostic testing company focused primarily on oncology. The company develops and commercializes protein-based and phosphoprotein-based assays intended to help physicians personalize cancer treatment decisions, particularly in breast cancer and other solid tumor indications. Public disclosures and company materials describe Theralink’s platform as combining molecular diagnostics, laboratory testing, and data analytics to identify signaling pathway activity and potential therapeutic targets.

The company’s principal revenue drivers have historically included laboratory-developed diagnostic testing services, biomarker analysis, and related precision oncology solutions offered to healthcare providers and biopharmaceutical stakeholders. Theralink operates within the broader molecular diagnostics and personalized medicine industries, serving oncologists, cancer centers, clinical researchers, and pharmaceutical partners. Its strategic positioning is tied to its focus on protein signaling analysis rather than solely genomic sequencing, which the company has presented as a differentiator in identifying active cancer pathways. Publicly available information indicates the company evolved from a diagnostic and translational medicine platform into a commercial precision oncology business through acquisitions, technology licensing, and laboratory expansion initiatives. Certain historical corporate development details vary across public disclosures, and some legacy ownership information remains inconclusive based on available public sources.